Skip to Content

TE VA 7629 (Imatinib mesylate 100 mg)

Pill imprint TE VA 7629 has been identified as Imatinib mesylate 100 mg.

Imatinib is used in the treatment of chronic myelogenous leukemia; gastrointestinal stromal tumor; acute lymphoblastic leukemia; chronic eosinophilic leukemia; dermatofibrosarcoma protuberans (and more), and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Imatinib 100 mg is not a controlled substance under the Controlled Substance Act (CSA).

Imatinib mesylate 100 mg TE VA 7629
Discount Card Promo
Imatinib mesylate
Imprint:
TE VA 7629
Strength:
100 mg
Color:
Brown
Shape:
Round
Availability:
Prescription only
Drug Class:
BCR-ABL tyrosine kinase inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Manufacturer:
Teva Pharmaceuticals USA, Inc.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide